Name:	pip_ContingentIndemnificationClaimsMinimumAmount
Namespace Prefix:	pip_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The period of time after the Court of Chancery of the State of Delaware renders a substantive decision on the merits in PharmAthene's civil case against SIGA within which the PharmAthene board of directors can determine, in its reasonable discretion, that, as a result of such decision, it can no longer consider the Merger a merger of equals.

No definition available.

Name:	pip_MaximumPeriodOfTimeAfterSubstantiveDecisionRenderedBoardMayDeemMergerUnequal
Namespace Prefix:	pip_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

If the registration statement on Form S-4 is not declared effective by October 4, 2013, then either party is generally entitled to extend the Outside Termination Date by 60 days.

No definition available.

Name:	pip_MergerAgreementOutsideTerminationDateExtension
Namespace Prefix:	pip_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Completion of the Merger is subject to a number of conditions, including, but not limited to (vii) all $8,000,000 of capital committed to Theraclone pursuant to its Series B-1 Preferred Stock and Warrant Purchase and Exchange Agreement shall have been delivered to Theraclone (which Theraclone has confirmed did occur).

No definition available.

Name:	pip_MergerCompletionConditionCommittedCapital
Namespace Prefix:	pip_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Completion of the Merger is subject to a number of conditions, including, but not limited to (v) exercise of appraisal rights by no more than 5% of Theraclone's stockholders.

No definition available.

Name:	pip_MergerCompletionConditionMaximumPercentageExerciseOfAppraisalRights
Namespace Prefix:	pip_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The Merger Agreement defines "Fully Diluted Equity" to mean, with respect to PharmAthene, the total number of shares outstanding of PharmAthene common stock assuming full conversion or exercise of all then outstanding options and warrants, which, in each case, have an exercise price less than or equal to $2.50 per share, and convertible securities.

No definition available.

Name:	pip_OptionsAndWarrantsOutstandingMaximumPricePerShareThresholdQualifyingAsFullyDilutedEquity
Namespace Prefix:	pip_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

PharmAthene common stock representing 5% of the merger consideration issuable to the stockholders of Theraclone, which will serve to secure the Theraclone stockholders' indemnification obligations under the Merger Agreement.

No definition available.

Name:	pip_PercentageOfMergerConsiderationIssableToTheracloneStockholdersToBeHeldInEscrow
Namespace Prefix:	pip_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The approximate percentage of ownership of security holders of PharmAthene and Theraclone, immediately prior to the Effective Time, each will own following the consumation of the transaction contemplated by the Merger Agreement (without regard to PharmAthene options and warrants having an exercise price greater than $2.50 per share) after the Merger.

No definition available.

Name:	pip_PercentagFullyDilutiveEquityAnticipatedFollowingMerger
Namespace Prefix:	pip_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

In certain other circumstances, PharmAthene will be obligated to reimburse Theraclone for expenses incurred in connection with the Merger, not to exceed $1,000,000.

No definition available.

Name:	pip_ReimbursementExpenses
Namespace Prefix:	pip_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The loss recognized on termination of a contract.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 912

-SubTopic 275

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6471736&loc=d3e54681-109401